Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Novavax, Inc.
Royal Philips’ image-guided therapy business has rebounded, as expected, after the COVID-19 dip, and is now targeting expansion in a number of areas, as business leader Bert van Meurs explains.
The UK’s choice of the mRNA vaccines as COVID-19 boosters is no surprise – but not releasing the key study data behind the decision is.
The European drugs regulator has given an overview of progress with the assessment of new vaccine candidates, additional and booster vaccines, and the use of vaccines in younger age groups.
A third death has been reported in Japan following dosing with Moderna's mRNA vaccine and while an investigation is underway, it is not seen as product-related. Takeda has also signed a production and supply deal with Japan's government for Novavax's nanoparticle vaccine.
- Drug Delivery
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- CPL Biologicals Pvt. Ltd. (Joint Venture with Cadila)
- Isconova AB
- Novavax AB